P.A.W. Capital Corp Invests $675,000 in OptimizeRx Corp. $OPRX

P.A.W. Capital Corp purchased a new position in OptimizeRx Corp. (NASDAQ:OPRX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $675,000. OptimizeRx accounts for 1.3% of P.A.W. Capital Corp’s investment portfolio, making the stock its 18th largest position. P.A.W. Capital Corp owned approximately 0.27% of OptimizeRx as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after buying an additional 1,818 shares during the period. MetLife Investment Management LLC bought a new position in OptimizeRx in the first quarter valued at approximately $99,000. Virtu Financial LLC acquired a new position in OptimizeRx during the first quarter valued at approximately $112,000. American Century Companies Inc. lifted its stake in OptimizeRx by 9.6% during the first quarter. American Century Companies Inc. now owns 15,783 shares of the company’s stock worth $137,000 after purchasing an additional 1,387 shares during the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of OptimizeRx in the 2nd quarter valued at $138,000. Institutional investors own 76.47% of the company’s stock.

Insider Activity at OptimizeRx

In related news, Director Patrick D. Spangler sold 11,120 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total value of $194,488.80. Following the sale, the director owned 44,215 shares of the company’s stock, valued at $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares of the company’s stock, valued at approximately $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Citigroup reissued an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. UBS Group set a $23.00 target price on shares of OptimizeRx in a report on Friday, October 10th. Roth Capital restated a “buy” rating on shares of OptimizeRx in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $14.12 on Wednesday. The firm has a market capitalization of $263.21 million, a price-to-earnings ratio of -26.15 and a beta of 1.24. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. The business’s 50-day moving average price is $18.51 and its 200-day moving average price is $15.51. OptimizeRx Corp. has a 12 month low of $3.99 and a 12 month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.17. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%.The company had revenue of $26.07 million during the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that OptimizeRx Corp. will post -0.33 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.